食管平滑肌瘤微创切除术:24年单中心经验
该回顾性队列研究纳入2000至2024年间53例经手术切除且病理确诊的食管平滑肌瘤患者,评估微创手术管理的安全性与有效性。结果显示,胸腔镜剜除术33例(62.3%)、腹腔镜剜除术13例(24.5%)、胸腔镜中转开胸剜除5例(9.4%)、微创食管切除术2例(3.8%);围术期并发症少见,无重大并发症或术后漏。结论认为微创剜除术安全有效,胸腔镜适用于近端至中段食管肿瘤,腹腔镜联合抗反流手术可能适用于距胃食管交界3 cm以内的远端肿瘤。
要点
- 微创剜除术治疗食管平滑肌瘤安全有效,围术期并发症率低。
- 胸腔镜剜除术适用于近端至中段食管肿瘤。
- 距胃食管交界3 cm以内的远端肿瘤,腹腔镜剜除联合抗反流手术可减少术后反流。
核心结论
- 微创剜除术可能是食管平滑肌瘤安全有效的治疗方法。
- 胸腔镜剜除术可能适用于近端至中段食管肿瘤。
- 腹腔镜剜除联合抗反流手术可能适用于距胃食管交界3 cm以内的远端肿瘤,以减少术后反流和未来手术干预需求。
研究设计与样本
- 单中心回顾性队列研究,纳入2000至2024年间53例经手术切除且病理确诊的食管平滑肌瘤患者。
- 排除其他黏膜下肿瘤(如GIST)、食管癌或接受内镜下切除的患者。
主要发现
- 手术方式包括胸腔镜剜除33例(62.3%)、腹腔镜剜除13例(24.5%)、胸腔镜中转开胸剜除5例(9.4%)、微创食管切除术2例(3.8%)。
- 平均肿瘤大小为4.92 cm。
- 术中黏膜损伤3例(5.7%),Clavien-Dindo ≤ II级术后并发症3例(5.7%),无重大并发症或术后漏。
- 平均住院时间为4天。
- 胸腔镜剜除组(平均肿瘤大小4.6 cm)吞咽困难为最常见症状(68.8%);腹腔镜组(平均肿瘤大小3.3 cm)反流为主(76.9%),7例(53.8%)同期行胃底折叠术(4例Nissen、2例Dor、1例Toupet)。
临床怎么用
- 对于近端至中段食管平滑肌瘤,可考虑胸腔镜剜除术。
- 对于距胃食管交界3 cm以内的远端肿瘤,可考虑腹腔镜剜除联合抗反流手术以降低术后反流风险。
局限性
- 单中心回顾性研究,样本量较小(53例),可能存在选择偏倚。
- 未报告长期随访结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Esophageal leiomyoma is the most common benign submucosal esophageal tumor, with enucleation as the preferred treatment. This study evaluates our institution's experience with minimally invasive surgical management of esophageal leiomyoma. METHODS: We conducted a retrospective cohort study of patients who underwent surgery for histologically confirmed esophageal leiomyoma between 2000 and 2024. Patients with other submucosal tumors (i.e. GISTs), esophageal carcinoma, or those who underwent endoscopic resection were excluded. RESULTS: 53 patients underwent surgical resection for esophageal leiomyoma during the 24-year study period. Surgical approaches included thoracoscopic enucleation in 33 patients (62.3%), laparoscopic enucleation in 13 patients (24.5%), thoracoscopic conversion to open enucleation in 5 patients (9.4%), and minimally invasive esophagectomy in 2 patients (3.8%). The mean tumor size was 4.92 cm. Perioperative complication rates were infrequent: intraoperative mucosal injury occurred in 3 patients (5.7%), and Clavien-Dindo grade ≤ II postoperative complications were reported in 3 patients (5.7%). Notably, there were no instances of major morbidity or postoperative leaks. The mean hospital length of stay was 4 days. Among patients who underwent thoracoscopic enucleation (mean tumor size: 4.6 cm), dysphagia was the most common presenting symptom (68.8%). In the laparoscopic group (mean tumor size: 3.3 cm), reflux was predominant (76.9%), and 7 patients (53.8%) underwent concomitant fundoplication (4 Nissen, 2 Dor, 1 Toupet). Persistent reflux occurred in 4 patients who did not have concurrent anti-reflux procedures (30.8% of laparoscopic cases), with two patients (15.4%) requiring subsequent fundoplications. CONCLUSIONS: Minimally invasive enucleation may offer a safe and effective treatment for esophageal leiomyoma. Thoracoscopic enucleation may be suitable for proximal to mid-esophageal tumors, while laparoscopic enucleation with anti-reflux surgery may be advisable for distal tumors within 3 cm proximal to the gastrointestinal junction to reduce postoperative reflux and the need for future surgical interventions.
引用
- Kim S, Luketich JD, Levy RM, et al. Minimally invasive resection of esophageal leiomyoma: 24 year experience. Surg Endosc. 2025. PMID: 41071212. doi:10.1007/s00464-025-12256-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。